Details for Patent: 11,255,842

Which drugs does patent 11,255,842 protect, and when does it expire?

Patent 11,255,842 protects TYMLOS and is included in one NDA.

This patent has twelve patent family members in twelve countries.

Summary for Patent: 11,255,842

Title:	Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog
Abstract:	The present disclosure is directed to methods (e.g., in vitro methods) for detecting the presence of neutralizing antibodies to PTH or PTHrP analog in a sample. The in vitro method comprises the steps of obtaining a sample from a subject; contacting the sample with a cell; measuring cyclic adenosine monophosphate (cAMP) levels; and detecting the presence of neutralizing antibodies when cAMP levels are reduced relative to a negative control sample without neutralizing antibodies. An in vitro method of detecting the presence of neutralizing antibodies in a sample from a subject treated with Abaloparatide, is also provided. Further provided herein is a kit for carrying out the methods described herein comprising components required to carry out the obtaining, contacting, measuring and detecting steps and instructions for use.
Inventor(s):	Chandler; Heidi K. (Boxborough, MA)
Assignee:	Radius Health, Inc. (Boston, MA)
Application Number:	17/369,163
Patent Claim Types: see list of patent claims	Use; Device;

Drugs Protected by US Patent 11,255,842

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Radius	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743-001	Apr 28, 2017		RX	Yes	Yes						USE FOR DETECTING NEUTRALIZING ANTIBODIES

International Family Members for US Patent 11,255,842

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2020207653
Brazil	112021011566
Canada	3122231